Literature DB >> 10469432

Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.

B Weiss1, G Bollag, K Shannon.   

Abstract

The NF1 gene encodes neurofibromin, a GTPase-activating protein (GAP) for members of the p21(ras) (Ras) family, which negatively regulates Ras output by accelerating the conversion of active Ras. GTP to inactive Ras.GDP. Analysis of tumors from patients with neurofibromatosis type 1 (NF1) has shown biochemical evidence of hyperactive Ras as well as frequent loss of the normal NF1 allele, consistent with its role as a tumor suppressor gene. Taken together, these data suggest that novel therapeutics directed against components of the Ras signaling cascade might provide effective treatments for certain pathological complications of NF1. Here we summarize data that support a role for hyperactive Ras in NF1 disease, including Ras processing, activation, and down-regulation. We review targets for rational drug design, provide preliminary results, and discuss implications for future studies. Am. J. Med. Genet. (Semin. Med. Genet.) 89:14-22, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469432

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  30 in total

Review 1.  Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

Authors:  C Shilyansky; Y S Lee; A J Silva
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

Review 2.  Current status of MEK inhibitors in the treatment of plexiform neurofibromas.

Authors:  Andrea M Gross; Eva Dombi; Brigitte C Widemann
Journal:  Childs Nerv Syst       Date:  2020-06-30       Impact factor: 1.475

3.  Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors:  Brigitte C Widemann; Eva Dombi; Andrea Gillespie; Pamela L Wolters; Jean Belasco; Stewart Goldman; Bruce R Korf; Jeffrey Solomon; Staci Martin; Wanda Salzer; Elizabeth Fox; Nicholas Patronas; Mark W Kieran; John P Perentesis; Alyssa Reddy; John J Wright; AeRang Kim; Seth M Steinberg; Frank M Balis
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

Review 4.  Adrenocortical tumorigenesis: Lessons from genetics.

Authors:  Crystal D C Kamilaris; Fady Hannah-Shmouni; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2020-05-23       Impact factor: 4.690

Review 5.  Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Multidisciplinary Recommendations for Care.

Authors:  Robert A Avery; James A Katowitz; Michael J Fisher; Gena Heidary; Eva Dombi; Roger J Packer; Brigitte C Widemann
Journal:  Ophthalmology       Date:  2016-11-03       Impact factor: 12.079

6.  Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.

Authors:  Vincent Chau; S Kyun Lim; Wei Mo; Chiachi Liu; Amish J Patel; Renée M McKay; Shuguang Wei; Bruce A Posner; Jef K De Brabander; Noelle S Williams; Luis F Parada; Lu Q Le
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

7.  Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells.

Authors:  Xiaodong Zhou; Sung-Hoon Kim; Ling Shen; Hyo-Jung Lee; Changyan Chen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

9.  Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.

Authors:  Yangsook Song Green; Timothy Sargis; Ethan Conrad Reichert; Eleanor Rudasi; Daniel Fuja; Eric Jonasch; Mei Yee Koh
Journal:  Mol Cancer Res       Date:  2019-01-31       Impact factor: 5.852

Review 10.  Genetics of the hamartomatous polyposis syndromes: a molecular review.

Authors:  Hui-Min Chen; Jing-Yuan Fang
Journal:  Int J Colorectal Dis       Date:  2009-04-21       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.